Drug Discovery App CS WP

  1. How Lipid Nanoparticles Enable Next-Gen Delivery 10/20/2025

    Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.

  2. Why Biopharma Breakthroughs Aren't Moving The Market 10/20/2025

    Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.

  3. Optimization And Scale-Up Of A Plasmid DNA Production Process 9/30/2025

    Optimizing pDNA production in E. coli requires strategic media selection and scale-up planning. Explore a study that identifies ideal conditions for high-yield manufacturing.

  4. Overcoming Unique Client Challenges With A Strong Collaborative Partnership 9/23/2025

    Through close collaboration, proactive communication, and agile project management, our partnership accelerated an oncology program and helped overcome complex preclinical hurdles.

  5. BxPC-3: Evaluating Responses To Standard Therapeutic Agents 9/23/2025

    Review multiple studies utilizing the BxPC-3 human pancreatic cancer model in subcutaneous (SC) NSG and NSG-dKO mouse models, evaluating a range of standard agents, vehicles, and delivery methods.

  6. A Risk-Based Approach To Plasmid DNA And mRNA Process Development 9/23/2025

    Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

  7. Preclinical Technique To Assess Targeted Therapies For Primary, Metastatic NSCLC 9/13/2025

    To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

  8. Characterize Your PROTAC Hook Effect With Flexible In-Solution Affinity Measurements 9/3/2025

    Characterizing the PROTAC hook effect is crucial for selecting candidates with enhanced cooperativity. Gain confidence with flexible, in-solution affinity measurements that reveal key biophysical parameters and align with established three-component binding models.

  9. Aggregation In Antibody-Drug Conjugates: Causes And Mitigation 9/1/2025

    Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

  10. Time To Intensify: Taking mAb Manufacturing To The Next Level 8/19/2025

    Explore how process intensification can revolutionize monoclonal antibody manufacturing to boost productivity, cut costs, and enhance sustainability with scalable strategies and real-world results.